MAHIDOL OXFORD TROPICAL MEDICINE

Mahidol Oxford Tropical Medicine Research Unit (MORU) is neither a factory nor a trading company. It is a research unit.

Company Introduction:

The Mahidol Oxford Tropical Medicine Research Unit (MORU) is a world-leading collaborative research program. Established in 1980, it is a partnership between Mahidol University in Thailand and the University of Oxford in the United Kingdom.

MORU's core mission is to conduct high-quality clinical and public health research to improve the health of people living in tropical regions, with a primary focus on Southeast Asia and Africa. Its extensive research portfolio encompasses a broad spectrum of infectious diseases, including but not limited to malaria, tuberculosis, HIV, dengue, influenza, bacterial infections, and emerging infectious diseases.

The unit is dedicated to translating its research findings into practical strategies, clinical guidelines, and public health policies. These are designed to effectively prevent, diagnose, and treat tropical diseases. Beyond its research endeavors, MORU also plays a vital role in training and capacity building for scientists and healthcare professionals across the region, nurturing the development of future experts in tropical medicine.

In summary, MORU is a prominent scientific institution focused on medical research and public health, and is not involved in manufacturing or commercial trading activities.

The Mahidol Oxford Tropical Medicine Research Unit (MORU) is primarily a research collaboration focused on tropical medicine, particularly:

Research and Clinical Trials related to:

* Malaria (treatment, drug resistance, pathophysiology)

* Melioidosis

* Scrub and Murine Typhus

* Drug-Resistant Infections

* Causes and Treatment of Rural Fever

* Sepsis

* CNS Infections

* Critical Care Medicine

* Maternal and Neonatal Health

* Tuberculosis (TB)

* Chagas Disease

* COVID-19 (antiviral pharmacodynamic trials like PLATCOV)

* Medicine Quality

* Antimicrobial Drug Resistance

MORU's focus is on developing and testing **appropriate, practical, and affordable interventions** (including drugs, treatment regimens, and healthcare methods) to improve global health, rather than the commercial production or sale of consumer products. Specific tangible products may include:

* **Clinical Research Findings and Publications** (e.g., demonstrating the efficacy of treatments like intravenous artesunate for severe falciparum malaria)

* **Healthcare Methods and Systems** developed from their research

* **Investigational Drugs or Vaccines** developed and tested through their clinical trials (though typically commercialized by pharmaceutical partners, not MORU itself)

* **Diagnostic Tools or Techniques** developed as part of their studies